By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aclaris Therapeutics 

101 Lindenwood Drive
Suite 400
Malvern  Pennsylvania  19355  U.S.A.
Phone: 484-324-7933 Fax: 484-324-7949



Company News
Aclaris (ACRS) Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/15/2017 8:38:46 AM
Aclaris (ACRS) Submits New Drug Application For A-101 As A Novel Treatment For Seborrheic Keratosis – A Common Skin Condition 2/27/2017 7:58:18 AM
Aclaris (ACRS) To Announce Fourth Quarter And Full Year 2016 Financial Results On March 15, 2017 2/23/2017 11:13:35 AM
Aclaris (ACRS) Release: Pharma Announces Appointment Of Andrew Powell To Board Of Directors 1/26/2017 7:37:22 AM
Aclaris (ACRS) Initiates Phase I Clinical Trial For ATI-50001, An Investigational JAK Inhibitor, For The Treatment Of Alopecia Totalis And Alopecia Universalis 12/7/2016 7:54:04 AM
Aclaris (ACRS) Announces Pricing Of Public Offering Of Common Stock 11/18/2016 7:27:30 AM
Aclaris (ACRS) Announces Proposed Public Offering Of Common Stock 11/17/2016 7:46:55 AM
Aclaris (ACRS) Announces Positive Top-Line Phase III Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition 11/16/2016 8:02:05 AM
Aclaris (ACRS) Reports Third Quarter 2016 Financial Results 11/3/2016 10:49:14 AM
Aclaris (ACRS) Submits Investigational New Drug Application For ATI-50001 To Treat Alopecia Universalis And Alopecia Totalis 10/31/2016 8:01:25 AM